Salix Pharmaceuticals Ltd

Summary

Introduction

Salix's main focus is to develop and market prescription drugs used in the treatment of various gastrointestinal diseases. Specifically, the company adopts in-licensing by entering into license and marketing agreements to acquire, develop and commercialize prescription drugs used in the treatment of gastrointestinal diseases.

Scope

• Contains corporate strategy, value chain presence and SWOT Analysis
• Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
• Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Salix is a specialty pharmaceutical company engaged in the development, sale and marketing of prescription pharmaceuticals. The company has a portfolio of in-licensed products that includes: Anusol, Azasan, Colazal, MoviPrep, OsmoPrep, Pepcid, Proctocort, Visicol and Xifaxan.

Salix derives its revenues from product sales which mainly comprise of sales of its in-licensed products. The company's total revenues increased at a CAGR of 58.0% during 2002-2006, from $33 million to $209 million.

The company's biggest contributor to sales growth out to 2010 will be the sales of Colazal, used in pediatric patients between 5 to 17 years of age with ulcerative colitis Revenues from Colazal sales is expected to increase at a CAGR of 16%, from $104 million in 2006 to $185 million in 2010.

Reasons to Purchase

• Access all the important information and analysis on the company in a single report
• Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
• Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Contents

• Overview
• Catalyst
• Summary
• Company Structure
  • Company Overview And Key Facts
  • Business Description
  • History
  • Company Financials
  • Stock Market Performance
  • P&L
  • Balance Sheet
  • Cash Flow
  • Products & Services
  • Marketed Products
  • Pipeline Products
  • Historical Product Sales
  • Ac Forecast Product Sales
  • Competitors And Strategic Business Relationships
  • Key Competitors
  • Key Suppliers
  • Key Clients
  • Shareholding Structure
  • Strategy
  • Company View
  • Corporate Strategy
  • Swot Analysis
  • Overview
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats
  • Value Chain Analysis
  • Overview
  • Product Development
  • Manufacturing
  • Sales
  • Scorecard
  • Overview
  • Scorecard Analysis
  • Key Employees
  • List Of Key Employees
  • Key Employee Biographies
  • Financial And Operational Overview
  • Financial And Operational Overview
• Appendix
• Ask The Analyst
• Datamonitor Consulting
• Disclaimer
• Table Of Figures
  • Figure 1: Salix - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
  • Figure 2: Salix - Key Strategic Revenues, 2002-2006 ($ Mn)
  • Figure 3: Salix - Key Strategic Revenues, 2006-2010 ($ Mn)
• Table Of Tables
  • Table 1: Salix - Key Facts
  • Table 2: Salix - Year-End Share Price And Market Capitalization, 2002-2006 ($)
  • Table 3: Salix - Key Events Impacting Share Price Performance
  • Table 4: Salix - Operating Revenue / Cost Analysis, 2002-2006 ($Mn)
  • Table 5: Salix - Operating Cost Ratio Analysis, 2002-2006 (% Of Total Revenues)
  • Table 6: Salix - Balance Sheet, 2002-2006 ($ Mn)
  • Table 7: Salix - Cash Flow, 2002-2006 ($ Mn)
  • Table 8: Salix - Marketed Products
  • Table 9: Salix - In-House Pipeline Products
  • Table 10: Salix - Historical Product Sales, 2002-2006 ($ Mn)
  • Table 11: Salix - Forecast Sales, 2006-2010 ($ Mn)
  • Table 12: Salix - Key Competitors
  • Table 13: Salix - Key Suppliers
  • Table 14: Salix - Key Shareholders
  • Table 15: Salix - Swot Analysis Summary
  • Table 16: Salix - Value Chain Analysis
  • Table 17: Salix - Scorecard
  • Table 18: Salix - Key Employees
  • Table 19: Salix - Financial And Operational Overview